Innovent Biologics and Daiichi Sankyo Reach Vanflyta Commercialization Agreement in China
2026-08-10 10:53:44
According to CoinMeta, Innovent Biologics Inc ( IVBXF, 1801. HK ) has reached an exclusive agreement with Daiichi Sankyo ( DSKYF, 4568.T ) to obtain the commercialization rights of Vanflyta ( Quizartinib ) in China. Innovent Biologics stated in a declaration that both parties have signed the relevant agreement.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.